VY-AADC01 gene therapy in Parkinson’s disease: Interim results of the on-going Phase 1b PD-1101 trial
Objective: Evaluate the safety of VY-AADC01, an AAV2 gene therapy vector with human aromatic L-amino acid decarboxylase (AADC) administered bilaterally to the putamen using intraoperative…SURE-PD3 Trial Participant Features prior to Randomization
Objective: To describe the cohort screened and randomized into the Study of Urate Elevation in Parkinson’s Disease, phase 3 (SURE-PD3) trial (NCT02642393). Background: The SURE-PD3…It takes two to tango but following may be more beneficial for rehabilitating people with mild-moderate Parkinson’s
Objective: This study determined the efficacy of internally guided (leading) versus externally guided (following) in adapted tango versus a contact-matched control group (wellness education) for…Neurorestorative effects of glycine transporter 1-inhibitor and D-Serine in a mouse model of nigrostriatal dopaminergic degeneration
Objective: We set out to evaluate potential neurorestorative effects of the GlyT1 inhibitor ACPPB vis-à-vis D-Serine in the intrastriatal 6-OHDA mouse model of Parkinson’s disease.…Surface mechanised nano-formulation of naringenin as adenosine A2A receptor antagonist against in Neurological associated problem of Parkinson
Objective: In the current experimental study, we intended to develop Surface mechanized nano-formulation of naringenin (NG) as potent A(2A)AR antagonists against parkinson’s disease. Background: One…Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)
Objective: To evaluate novel retention strategies in an ongoing phase 3 clinical trial in individuals with Parkinson disease (PD) Background: Adequate participant retention is a…Drug utilization characteristics in individuals with early Parkinson’s disease interim analysis of the STEADY-PD III study
Objective: To review symptomatic therapy (ST) utilization trends in individuals with early Parkinson’s disease (PD). Background: There are changing trends in ST utilization in early…Case study: Real-time MRI articulatory comparison of a congenital aglossic and normal speaker
Objective: Congenital aglossia is a rare syndrome of born without a tongue. This paper examines articulatory movements of a congenital aglossic speaker to understand physiology by…The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
Objective: Develop a quantitative tool to optimize the definition of entry criteria, enrichment strategies and stratification approaches, and submit for formal regulatory endorsement at FDA…Treatable Rare Movement Disorders
Objective: To classify therapies of RMD into enzyme replacement therapy, specific dietary changes, avoidance or management of certain triggers, and others Background: Rare diseases (RD)…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- 16
- Next Page »